Chicago, IL and Santa Clara, CA 2/3/10—Agilent Technologies has sold Hycor Biomedical, which it acquired through its purchase of Stratagene (see IBO 4/15/07), to private equity firm Linden. Terms of the agreement were not disclosed. Hycor develops, manufacturers and markets in vitro diagnostic products for the allergy, autoimmune and urinanalysis markets. “Hycor is an innovative, profitable, and growing business, but it does not fit the core focus of our life science business,” commented Nick Roelofs, president of Agilent’s Life Sciences Group.